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BACKGROUND: The clinico-pathological and molecular heterogeneity of epithelial ovarian cancer (EOC) complicates its early diagnosis
and successful treatment. Highly aneuploid tumours and the presence of ascitic fluids are hallmarks of EOC. Two microcephaly-
associated proteins, abnormal spindle-like microcephaly-associated protein (ASPM) and microcephalin, are involved in mitosis and
DNA damage repair. Their expression is deregulated at the RNA level in EOC. Here, ASPM and microcephalin protein expression in
primary cultures established from the ascites of patients with EOC was determined and correlated with clinical data to assess their
suitability as biomarkers.
METHODS: Five established ovarian cancer cell lines, cells derived from two benign ovarian ascites samples and 40 primary cultures of
EOC derived from ovarian ascites samples were analysed by protein slot blotting and/or immunofluorescence to determine ASPM
and microcephalin protein levels and their cellular localisation. Results were correlated with clinico-pathological data.
RESULTS: A statistically significant correlation was identified for ASPM localisation and tumour grade, with high levels of cytoplasmic
ASPM correlating with grade 1 tumours. Conversely, cytoplasmic microcephalin was only identified in high-grade tumours.
Furthermore, low levels of nuclear microcephalin correlated with reduced patient survival.
CONCLUSION: Our results suggest that ASPM and microcephalin have the potential to be biomarkers in ovarian cancer.
British Journal of Cancer (2011) 104, 1602–1610. doi:10.1038/bjc.2011.117 www.bjcancer.com
Published online 19 April 2011
& 2011 Cancer Research UK
Keywords: epithelial ovarian cancer; ovarian ascites; ASPM; microcephalin; biomarkers
                                                     
Epithelial ovarian cancer (EOC) remains one of the deadliest
gynaecological cancers with more than 204000 new cases being
diagnosed worldwide each year (Cancer Research UK, 2010). The
cancer is characterised by presentation with advanced disease, a
high rate of recurrence despite response to primary surgery/
chemotherapy and ultimately low survival; a median overall
survival of 3–4 years was defined in a recent international phase
III clinical trial (Bookman et al, 2009). There is a need to better
characterise these tumours to identify markers of poor prognosis,
which may be used to guide subsequent management.
A consistent clinical feature of advanced EOC is the accumula-
tion of ascitic fluid in the peritoneum of patients. Large volumes of
fluid from patients with newly diagnosed or recurrent EOC can be
taken at the time of primary surgery or therapeutic paracentesis
and have been shown to be a useful source of malignant ovarian
cancer cells for the study of EOC with regards to immunology,
gene expression and drug development (Parella et al, 2003; Graves
et al, 2004; Bamias et al, 2007). The genes MCPH5 encoding
abnormal spindle-like microcephaly-associated protein (ASPM)
and MCPH1 encoding microcephalin have been shown to be
associated with autosomal primary microcephaly, a developmental
brain disorder characterised by an architecturally normal but small
brain and associated mental retardation (Aicardi, 1998; Bond et al,
2002, 2003; Jackson et al, 2002). In interphase, ASPM has a
predominantly centrosomal or nuclear localisation (Zhong et al,
2005; Higgins et al, 2010). It has an important role in mitosis while
localised to the pericentrosomal matrix surrounding the mitotic
spindle (Fish et al, 2006; Higgins et al, 2010). Microcephalin is
involved in DNA damage repair and a cell cycle control pathway
that prevents premature entry into mitosis (Trimborn et al, 2004;
Rai et al, 2006). It has a reported centrosomal localisation (Zhong
et al, 2006; Tibelius et al, 2009), while a nuclear localisation has
been reported in immunofluorescence (Rai et al, 2006) and
immunohistochemistry (IHC; Rai et al, 2006, Human Protein Atlas
(http://www.proteinatlas.org)). We hypothesised that as mitosis-
and DNA repair-associated proteins, ASPM and microcephalin,
might have a role in the tumourigenesis of cancers with highly
aneuploid tumours, such as high-grade EOC. Recently, both ASPM
and microcephalin have been shown to be deregulated in a variety
of cancers (Bartek, 2006; Horvath et al, 2006; Hagemann et al,
2008; Kabbarah et al, 2010; Richardson et al, 2010). Publications
relating specifically to EOC have demonstrated an upregulation of
mRNA levels for ASPM and a decrease for microcephalin
(Kouprina et al, 2005; Rai et al, 2006). We investigated ASPM
and microcephalin in established ovarian cancer cell lines and in
primary cultures derived from ovarian ascites to determine
Received 7 October 2010; revised 9 March 2011; accepted 13 March
2011; published online 19 April 2011
*Correspondence: Dr SM Bell; E-mail: medsmb@leeds.ac.uk
British Journal of Cancer (2011) 104, 1602–1610
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swhether their expression is altered at the protein level in this
cancer. We then ascertained whether correlations with associated
clinical data could be useful prognostic markers in EOC. Here, we
demonstrate for the first time that ASPM and microcephalin
protein expression is deregulated in primary cultures of malignant
cells obtained from ascitic fluids of EOC patients and that this
expression shows an association with survival or tumour grade.
Potentially, both ASPM and microcephalin may be useful
biomarkers for EOC.
MATERIALS AND METHODS
Patient samples and cell lines
The sample panel consisted of five established ovarian cancer cell
lines (1847, TRI75, SKOV-3, JAMA-2 and OVCA433), all obtained
from Cancer Research UK, and cells from 40 primary cultures of
EOC derived from ovarian ascites samples collected from patients
receiving treatment at St James’s Hospital Institute of Oncology.
Also included were primary cultures established from the
peritoneal washings of two patients who were found to have
benign epithelial neoplasms (1153-A1, serous cystadenoma and
1078-A1, mucinous cystadenoma). Ethical approval was obtained
for all clinical samples involved in this study from the local
Research Ethics committee of the Leeds Teaching Hospitals NHS
Trust, Leeds.
Establishment of primary cultures from ovarian ascites
On receipt, ascites samples were processed aseptically as described
previously (Ingram et al, 2010). Briefly, ascites were centrifuged at
2000r.p.m. to separate the cells from the ascitic supernatant. The
decanted supernatant was reserved for use as a cell culture
supplement. Contaminating red blood cells were removed by
10min treatment with red blood cell lysing buffer (Sigma-Aldrich,
Poole, UK) according to manufacturers’ instructions. Cell pellets
were resuspended in RPMI 1640 medium supplemented with 10%
FCS and, additionally at passage (p) 0, with 10% decanted autologous
supernatant, and were incubated in 25–75cm
2 flasks in a 5% CO2
incubator at 371C. Once cells were confluent they were trypsinised
and passaged at a 1/3 dilution. Passage levels were kept low to
minimise phenotypic changes due to adaptation to cell culture.
Antibodies
The rabbit affinity-purified ASPM antibody 216-1 and the rabbit
affinity-purified microcephalin antibody (Abcam, Cambridge, UK
ab2162) were used throughout this study. Although information on
the specificity of these antibodies has been previously published
(Xu et al, 2004; Higgins et al, 2010), we further confirmed the
specificity of the immunofluorescence staining by pre-incubation
with peptides for both antibodies (Supplementary Figures 1A–C)
and by siRNA for microcephalin (Supplementary Figure 1D).
Slot blotting
To compare ASPM protein levels in established cancer cell lines,
benign samples and primary cultures, a slot blotting technique was
applied. Both primary cultures and cell lines were grown in 75cm
2
flasks until confluent. The cells were washed with PBS. Fresh PBS
(10ml) was added and the cells were detached using cell scrapers.
The cells were pelleted by centrifugation for 5min at 1000r.p.m.,
resuspended in 1ml of ice-cold RIPA buffer (50mM Tris-HCL pH 8,
150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
5m M EDTA and Roche ‘Complete’ protease inhibitor cocktail
(Roche, Welwyn Garden City, UK)) and transferred to Eppendorf
tubes. To promote lysis the cells were passed repeatedly through a
19-gauge needle after which the samples were placed on ice for
15min before being transferred to a microcentrifuge and spun for
30min at 13000r.p.m. at 41C. The supernatants were carefully
removed and aliquots were stored at  201C until further use.
Protein estimation was performed using the Modified Bradford
method (Bio-Rad protein assay, Bio-Rad Laboratories, Hemel
Hempstead, UK). Samples with a total protein concentration of
0.5mgml
 1 or more were analysed by slot blotting including 4 cell
lines, 1 benign sample and 32 primary cultures.
For slot blotting, protein lysates were diluted in RIPA buffer to a
concentration of 0.1mgml
 1 of protein and heated to 951C for
5min. A volume of 100ml of the diluted cell lysate solution was
loaded onto nitrocellulose supported by a pre-wetted Whatman
filter paper (Whatman International Ltd, Maidstone, UK) con-
tained within a slot blot apparatus (SCIE-PLAS, Cambridge, UK)
according to the manufacturers’ instructions. Lysate protein was
transferred onto the nitrocellulose in individual slots by applying a
vacuum of 0.8 atmospheres for 2min. All slots were washed with
100ml of PBS with pressure reapplied for 2min. The nitrocellulose
was removed from the slot blotter apparatus and blocked with 1%
non-fat dried milk in PBS for 30min on a rocker at room
temperature. Rabbit anti-ASPM antibody 217-2 (Higgins et al,
2010) at 1/200 in non-fat dried milk in PBS or rat anti-tyrosinated
a-tubulin (endogenous control, Transduction Laboratories, Lex-
ington, KY, USA) at 1/3000 was added to the nitrocellulose and
incubated for 1h at room temperature. After three washes for
5min each in PBS-Tween (0.1%) the nitrocellulose was incubated
in the secondary antibody solutions, anti-rabbit or anti-rat IgG-
horseradish peroxidase (Pierce ECL Femto kit, Pierce, Cramling-
ton, Northumberland, UK) at 1/50000 in non-fat dried milk in PBS
for another hour on a rocker at room temperature. The
nitrocellulose was washed three times for 5min in PBS-Tween
and once in PBS only. The Pierce SuperSignal West Femto ECL
reagent (Pierce) was added to the nitrocellulose membrane and
incubated for 5min. Signals were recorded using a Bio-Rad
ChemiDoc XRS system (Bio-Rad). The slot blot images from three
repeats for each sample were scanned and band densities analysed
to determine relative levels of ASPM and of tyrosinated a-tubulin
using Bio-Rad Quantity 1 software (Bio-Rad). After background
levels were subtracted the resulting values were examined as a ratio
of ASPM/a-tubulin for each sample, with high values representing
the samples with highest ASPM protein levels. Cutoff points were
determined to classify samples as having low, medium or high
ASPM levels.
Indirect immunofluorescence
Primary cultures and cell lines were grown on sterile coverslips in
6-well tissue culture dishes (Nunc, Thermo Fisher Scientific,
Roskide, Denmark) until they reached at least 75% confluency. The
cells were washed in PBS and fixed with ice cold 100% methanol at
 201C for 2min. After removal of the methanol, the cells were
incubated in 0.5% non-fat dried milk in PBS for 10min to block
non-specific antibody-binding sites. The rabbit anti-ASPM anti-
body 216-1 (1/500) (Higgins et al, 2010), the rabbit anti-
microcephalin antibody (1/100, Abcam, ab2612) and a rat anti-a-
tubulin antibody (1/500, Serotec, Kidlington, UK) were prepared in
blocking solution (0.5% non-fat dried milk in PBS). They were
spun for 5min in a microfuge at 13000r.p.m. before use.
Coverslips were inverted over a 200ml drop of this supernatant
on parafilm in a humidified chamber for 1h at room temperature,
then returned to the 6-well dish for washing. After three washes in
PBS for 5min each, the coverslips were incubated in secondary
antibody solution containing a mixture of goat anti-rabbit IgG
Alexa fluor 488 (1/500, Molecular Probes, Invitrogen, Paisley, UK),
goat anti-rat IgG Alexa fluor 568 (1/500, Molecular Probes) and
DAPI (5mgml
 1) diluted with the blocking solution and spun for
5min at 13000r.p.m. before introduction to the cells. After a
further incubation for 1h in a humidified chamber at room
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stemperature, the coverslips were washed four times in PBS for
5min each and then mounted onto microscope slides using
Mowiol (Sigma). Slides were allowed to set overnight and viewed
using a Zeiss Axiovert 200 fluorescence microscope (Zeiss, Welwyn
Garden City, UK) with a  63 Plan Apo oil immersion lens. Images
were captured and processed using a Hamamatsu Orca ER cooled
CCD camera (Hamamatsu, Hamamatsu City, Japan) and Andor IQ
imaging software (Belfast, UK).
Determination of protein levels in primary cultures and
cell lines by immunofluorescence
We determined the levels and localisation of ASPM (n¼22) and
microcephalin immunofluorescence (n¼36) in the cell lines and
in the primary cultures for comparison with the associated clinical
data. Five hundred to one thousand cells were observed for
staining profiles and quantification of fluorescence intensities was
performed for each sample in each of 20 interphase cells and at
least 20 mitotic cells using Andor IQ software. Samples containing
o20 mitotic cells per 1000 cells were not included in the mitotic
analysis. For microcephalin, nuclei were identified by DAPI
staining and the fluorescence within the nucleus measured and
divided by the area to give the integrated intensity per unit area.
The same method was applied for establishing nuclear ASPM and
cytoplasmic fluorescence levels. For ASPM levels in mitotic cells,
the fluorescence intensity within a defined region covering each
spindle pole at metaphase was recorded and the sum of intensities
for both spindle poles was determined. All recorded data were
examined and subsequently presented as weak, medium or strong
after establishing logical cutoff points for each category.
Statistical analysis of slot blot and fluorescence data
Associations between clinical variables and ASPM or microcephalin
proteins in the primary cultures were undertaken using Fisher’s
Exact test for categorical variables (site, disease stage, grade and
morphology at presentation) and the non-parametric Kruskall–
Wallis and Wilcoxon–Mann–Whitney test for continuous vari-
ables. The association between ASPM or microcephalin and
survival data was evaluated using the Kaplan–Meier method of
estimating survival functions and Cox proportional hazards
regression. All analysis was undertaken in the R Environment
for Statistical Computing (R Design Core Team, Vienna,
Austria).
04 0 20 60 80 100
0
10
20
30
40
50
60
70
80
90
100
110
120
130
140
High
Medium 
Low 
Grade 3  Grade 2  Grade 1
T
o
t
a
l
 
A
S
P
M
 
l
e
v
e
l
 
i
n
c
e
l
l
 
l
y
s
a
t
e
s
 
(
%
)
Tumour grade Time  (months) 
0.0
0.2
0.4
0.6
0.8
1.0
Cell lines Primary cultures
Anti-ASPM
Anti -tubulin
0
2
A
S
P
M
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
(
A
S
P
M
/
t
u
b
u
l
i
n
 
r
a
t
i
o
)
4
6
8
10
12
1
0
9
7
-
A
1
1
1
3
4
-
A
1
1
1
2
1
-
A
1
1
1
0
6
-
A
1
1
1
3
4
-
A
1
1
1
2
6
-
A
1
1
1
2
3
-
A
1
1
1
0
4
-
A
1
1
1
0
5
-
A
1
1
1
3
7
-
A
1
1
1
2
4
-
A
1
1
1
2
7
-
A
1
A
E
6
7
9
2
-
A
1
1
1
0
8
-
A
1
1
1
1
4
-
A
1
1
1
0
0
-
A
1
1
1
3
1
-
A
1
1
1
9
4
-
A
1
1
0
5
9
-
A
1
1
1
2
0
-
A
1
1
1
3
2
-
A
1
1
1
2
2
-
A
1
1
0
4
5
-
A
2
0
1
1
0
-
A
1
2
1
1
4
5
-
A
1
1
1
4
3
-
A
1
1
1
1
7
-
A
1
1
1
0
1
-
A
1
1
1
3
3
-
A
1
1
1
1
0
-
A
1
1
1
1
3
-
A
1
1
1
2
5
-
A
1
1
1
5
3
-
A
1
S
K
O
V
-
3
1
8
4
7
J
a
m
a
-
2
TR I75
Sample 
Cell line
Benign
Primary cultures
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
Low, n=11
Medium/high, n=13
Figure 1 Abnormal spindle-like microcephaly-associated protein protein levels differ among primary cultures. (A) Slot blot profile of four established
ovarian cell lines (top left) and seven primary cultures of EOC (top right). Each band represents one sample (10mg) probed with the ASPM antibody 217-2.
Bottom row shows bands obtained for a-tubulin in the samples. (B) Slot blot profile for ASPM after normalisation against a-tubulin revealing a range of
ASPM protein levels among established cell lines, one benign sample (1153-A1) and primary cultures (n¼37). (C) ASPM levels increase with tumour grade.
(D) Kaplan–Meier survival plot showing longer survival for groups with low ASPM levels in comparison with medium/high ASPM levels.
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Patient data
Clinical data was available for 40 ovarian cancer patients from
which ascitic fluid was obtained to generate the primary cultures.
The mean age of the patient group was 62.2 years with a range of
26–85 years. In all, 35 out of 40 (87.5%) of the patients were over
50 years of age and 5 out of 40 (12.5%) were under 50 years of age.
Among the ovarian cancer patients, 3 out of 40 (7.5%) presented
with stage 1 ovarian cancer, 1 out of 40 (2.5%) stage 2, 30 out of 40
(75%) stage 3 and 6 out of 40 (15%) stage 4 disease. Grading and
tumour typing was performed on histological material according
to the FIGO grading system identifying 8 out of 40 (20%) of
patients with grade 1 tumours, 11 out of 40 (27.5%) with grade 2
tumours and 19 out of 40 (47.5%) with grade 3 tumours. One
sample was a borderline case (2.5%). One patient (2.5%) had been
given chemotherapy based on ascitic fluid cytology together with
elevated tumour markers (CA125, 1607; CEAo1.0) and radiolo-
gical features consistent with stage 3c primary peritoneal
carcinoma. It was not possible to grade this tumour based on
the cytological preparation. The majority of the carcinomas were
high-grade serous adenocarcinoma (33 out of 40, 82.5%), with the
remaining samples comprising low-grade serous cystadenocarci-
noma (2 out of 40, 5%), endometrioid and mucinous type (1 out
of 40 each, 2.5%) and a further group assigned serous carcinoma
(2 out of 40, 5%), which were post-chemotherapy samples. The
median survival times from diagnosis for the patients was 39
months with a range of 2.7–112.5 months.
ASPM expression determined by slot blotting
Previous publications have indicated that ASPM levels are
upregulated in various cancers at the RNA level (Kouprina et al,
2005; Lin et al, 2008). Our own Affymetrix gene expression array
data from a previous study composed of primary cultures derived
from ovarian ascites samples and their associated solid tumours
showed that mRNA expression levels differed significantly among
the samples (Supplementary Figure 2). A correlation between
expression in matched tumour and ascites samples was also shown
(ASPM correlation coefficient 0.6, microcephalin correlation
coefficient 0.43; Supplementary Figure 3). We wanted to assess if
such differences were reflected in protein levels using our ascites
data set and ovarian cancer cell lines. Analysis of the slot blot
data for ASPM revealed that there were differences in the ASPM
protein levels among the different ovarian cancer cell lines
(Figures 1A and B). JAMA-2 had the lowest expression of the four
established cell lines followed by TRI75 and 1847, with SKOV-3
having the highest (Figure 1B). Variation was also observed among
the primary cultures. The lysate from a benign cystadenoma case
(control, sample 1153-A1) had one of the lowest levels of ASPM
protein in comparison to the other primary cell culture lysates
(Figure 1B). Analysis of the data revealed that with increasing
tumour grade there was an increase in total ASPM protein in the
sample set (Figure 1C). Association studies of ASPM levels and
mitotic activity within the primary cultures showed no statistically
significant association of total ASPM levels with the number of
cells in mitosis. This confirmed that the increase in ASPM levels
with tumour grade was not simply due to an increase in mitotic
activity in high-grade samples (Supplementary Figure 4A). To
further validate these results, proliferation in tumour tissues from
18 patients with associated ascites was determined by Ki-67 IHC
staining. Abnormal spindle-like microcephaly-associated protein
levels as determined by slot blot of primary cell culture lysates
were not associated with Ki-67-staining patterns in the primary
tumour that generated the ascites (Supplementary Figures 4B and C).
Patients with low ASPM levels had a longer median survival (44.6
months) than patients with high ASPM levels (28.2 months;
Figure 1D). However, this observation was not significant at the
nominal significant level (HR¼2.030, 95% CI¼(0.486, 8.473),
P¼0.331). In addition, our slot blot analysis demonstrated that
there were significantly fewer deaths among patients with high
ASPM levels (1 out of 11 9%) when compared with patients with
low levels (7 out of 13 53.8% P¼0.036).
ASPM expression and localisation visualised by
immunofluorescence in primary cultures
Having established that at both the mRNA and protein levels there
were differences in ASPM expression among established ovarian
cancer cell lines and the primary cultures, we next investigated the
cellular localisation and expression levels of ASPM using
immunofluorescence. Staining with the ASPM antibody revealed
that there was cytoplasmic and nuclear staining in interphase cells
0
10
20
30
40
50
60
70
80
90
100
Strong
Medium
Weak
Spindle poles Cytoplasmic Nuclear
Staining pattern 
N
u
m
b
e
r
 
o
f
 
s
a
m
p
l
e
s
 
w
i
t
h
s
t
a
i
n
i
n
g
 
p
a
t
t
e
r
n
 
(
%
)
*
*
Figure 2 Immunofluorescence staining patterns of ASPM in primary
cultures. (A) In interphase ASPM can be found in the cytoplasm and the
nucleus (a, b; arrowhead indicates cytoplasmic and arrow indicates nuclear
staining), whereas in mitosis ASPM localises at the spindle poles (c; asterix
indicates spindle pole). Green staining indicates ASPM, red a-tubulin and
blue DAPI. Scale bars are 10mm (b) and 5mm (d). (B) Histogram
summarising staining patterns and frequencies observed for ASPM after
fluorescence quantification.
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Figure 3 Established ovarian cell lines and primary cultures display different ASPM levels after fluorescence quantification. (A) Histogram illustrating the
range of ASPM levels in the nucleus established by immunofluorescence (n¼21). Examples of nuclei with low (a, b) and high (c, d) ASPM levels are shown.
Green staining indicates ASPM, red a -tubulin and blue DAPI. Scale bars are 5mm. (B) Histogram illustrating the range of ASPM levels in the cytoplasm as
established by immunofluorescence. Examples of low (a, b) and high (c, d) cytoplasmic ASPM levels are shown (n¼22). Scale bars are 10mm (b) and 5mm
(d). (C) Histogram illustrating the range of ASPM levels at the spindle poles as established by immunofluorescence (n¼14). Examples of spindle poles with
low (a, b) and high (c, d) ASPM levels are shown. Scale bar is 5mm. Green staining indicates ASPM, red a-tubulin and blue DAPI. (D) Graph depicting an
association of cytoplasmic ASPM levels in primary cultures with tumour grade. High cytoplasmic ASPM levels are lost in high-grade tumours (P¼0.0351).
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sin all of the samples as well as spindle pole staining in mitotic cells
(Figure 2A). However, the staining patterns and intensity differed
among samples and were scored as weak/medium/strong expres-
sion at each localisation after quantifying fluorescence intensities.
Staining patterns in two samples (1078-A1 and 1153-A1, primary
cultures from peritoneal washes from patients with benign
gynaecological conditions) revealed weak nuclear and cytoplasmic
staining with medium ASPM labelling at the spindle poles
(Supplementary Figure 5A). It seems likely that these observations
represent typical ASPM localisations and expression levels in
‘normal’ control cells. The majority of the 18 tumour-derived
samples had both weak nuclear and weak cytoplasmic staining
(64.7 and 77.8%, respectively), whereas 50% of the samples had
weak mitotic ASPM staining. Medium staining was observed for
23.5% (nuclear), 11.1% (cytoplasmic) and 21.4% (spindle poles) of
cultures. Strong nuclear staining was observed in 11.8% of the
cultures, strong cytoplasmic staining in 11.1% and strong spindle
pole staining in 28.6% (Figure 2B). Analysis of the staining data
indicated that the majority of the primary cultures had nuclear-
and spindle pole-staining intensities similar to the intensities
obtained for the established cell lines. Only two samples (1134-A1
and 1108-A1) for both nuclear staining and cytoplasmic staining
and two samples (1140-A1 and 1105-A1) for spindle pole staining
had markedly higher levels of ASPM than were observed in the cell
lines (Figures 3A–C). Generally, levels of cytoplasmic staining
were most variable among the primary cultures (Figure 3B).
Statistical analysis for the 18 primary culture samples with
associated clinical data indicated that strong cytoplasmic ASPM
staining levels were significantly associated with a low tumour
grade (P¼0.0351; Figure 3D).
Expression profiles and localisation of microcephalin in
primary cultures
Immunofluorescence staining with the microcephalin antibody on
36 samples revealed three distinct staining patterns: nuclear,
cytoplasmic and nuclear foci. After establishing cutoff points
following calculation of staining intensities, microcephalin levels
in the nucleus were classified as weak, medium or strong for each
sample. Overall, nuclear microcephalin expression in the majority
of the samples fell into the medium or strong category.
Cytoplasmic staining was seen in only 25% of the samples with
all exhibiting a weak staining pattern. Twenty-five percent of the
samples displayed strong multiple nuclear foci staining with the
remaining samples displaying only one or two strong foci per
nucleus. Figure 4 shows examples of each staining pattern
(Figure 4A) and a summary of the microcephalin localisation
pattern (Figure 4B). The two control samples, 1078-A1 and 1153-
A1, displayed strong nuclear staining and strong foci staining was
also detected in 1153-A1 (Supplementary Figure 5B). These are
therefore likely to represent the ‘normal’ localisation and
expression level of microcephalin in cultured ovarian epithelial
cells. The most common staining pattern observed in the tumour-
derived primary cultures was nuclear staining (Figure 5A); there-
fore, the fluorescence data from these observations were plotted
for each individual primary culture sample in comparison to the
established cell lines (Figure 5B). The majority of the samples had
nuclear staining intensities similar to the cell lines with the
exception of 1108-A1 (markedly lower) and 1143-A1 (higher).
Clinical data were available for 32 primary cultures. Interestingly,
weak nuclear staining was found only in the higher-grade tumours
(moderately differentiated, grade 2, to poorly differentiated, high
grade 3). In primary cultures of all patients with well-differentiated
tumours (grade 1), medium or strong nuclear staining was
observed (Figure 6A). An absence of cytoplasmic microcephalin
immunostaining was observed in low/well differentiated (grade 1)
tumours, whereas cytoplasmic staining correlated with grade 2 and
3 tumours exclusively (P¼0.047; Figure 6B). This finding suggests
that there is a positive correlation between the aberrant
cytoplasmic localisation of microcephalin and tumour develop-
ment. No association was found between nuclear foci staining and
the clinical data.
Statistical analysis of the immunofluorescence data revealed
weak evidence of an association between survival and weak nuclear
microcephalin staining pattern (HR¼0.2311, 95% CI¼(0.045,
1.201), P¼0.081). The association indicates that patients with a
weak score have an increased hazard of death, which correlates
with the loss of nuclear staining and increase in cytoplasmic
staining seen in the higher tumour grades (Figure 6C).
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Figure 4 Immunofluorescence staining patterns of microcephalin in
primary cultures. (A) In interphase microcephalin can be found in the
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fluorescence quantification.
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sWe also examined ASPM and microcephalin expression using
IHC in 23 paraffin-embedded primary tumour samples from
patients whose ascites were used to generate primary cultures.
Importantly, staining patterns and intensities in these samples
were similar to those detected in the corresponding primary
cultures (Supplementary Figures 6A and B), confirming that the
cultures were a viable proxy for tumour tissue samples in this
study. In six cases, adjacent normal tissue was present, as well as
tumour, providing useful controls.
DISCUSSION
Epithelial ovarian cancer is a very heterogeneous disease.
Histologically there are at least four subtypes. The most common
subtype, serous carcinoma, can be classified on a molecular basis
into two major groups (type I, low-grade carcinomas and type II,
high-grade carcinomas) according to p53 (high-grade carcinomas;
Ahmed et al, 2010) or KRAS/BRAF (low-grade carcinomas)
mutations (Cho and Shih, 2009). Prognosis for patients with stage
1 disease ovarian cancers is generally very good and 5-year
survival rates are more than 90%. However, most ovarian cancers
are detected at an advanced stage resulting in a 5-year survival
rate of o25%. Chemoresistance is a common occurrence after
chemotherapy and tumour debulking. Furthermore, disease
incidence in women over 65 has increased by more than 40%
since the 1970s (Cancer Research UK, 2010). Therefore, there is a
great demand for biomarkers and new therapeutics to manage
EOC. The aim of our study was multifold. First, we wanted to
establish if the two MCPH gene products, ASPM and micro-
cephalin, were deregulated in EOC at the protein level. We also
aimed to investigate if there was an association between
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Figure 6 Nuclear and/or cytoplasmic microcephalin levels are associated
with tumour grade and survival. (A) Weak microcephalin levels in the
nucleus are associated with higher-grade tumours. (B) Cytoplasmic
microcephalin is only detected in higher-grade tumours (P¼0.047).
(C) Kaplan–Meier survival plot showing survival for groups with weak
nuclear microcephalin levels and medium/strong nuclear microcephalin
levels (P¼0.081).
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EOC, because ovarian cancers exhibit a high degree of aneuploidy
and these proteins are known to be involved in mitotic processes
and DNA repair. There has recently been an increased interest in
proteins associated with chromosomal instability and aneuploidy
in cancer. High expression of the mitotic kinase BubR1 was
demonstrated to be associated with aggressive clinico-pathological
parameters including advanced stage of disease, serous histology
and high-grade tumours in EOC (Lee et al, 2009). This protein was
shown to be a prognostic marker for recurrence-free survival rates
in EOC. Our final aim was therefore to examine whether ASPM and
microcephalin might be similarly useful as biomarkers in this
disease.
In our study, we utilised primary cultures of EOC derived from
ascites. Malignant cells derived from ascitic fluids have recently
been used for the study of drug response and novel treatment
regimes (Ingram et al, 2010; Scarberry et al, 2010). Affymetrix gene
expression array data showed that the mRNA levels of both ASPM
and microcephalin varied between primary cultures grown from
malignant ascites and correlated with levels observed in primary
cultures derived from their associated primary tumours (Supple-
mentary Figure 1). In the present study, these primary cultures
were an ideal resource as we were able to clearly define
intracellular localisations and quantify protein levels of ASPM
and microcephalin in malignant cells, which is difficult to achieve
by other techniques such as FACS or IHC on solid tumour
samples. Analysis of ASPM in our primary cultures by slot blotting
revealed that high ASPM levels were mainly seen in grade 3 tumour
patients and were associated with reduced survival. Abnormal
spindle-like microcephaly-associated protein and microcephalin
immunofluorescence indicated that protein levels and localisations
varied among the samples, though this data should be interpreted
cautiously given the possibility that differently localised pools of
protein might be differentially extracted by the immunostaining
procedure. Nevertheless, variations in protein localisation ap-
peared to be significant for tumour development. High levels of
ASPM in the cytoplasm were associated with reduced tumour
grade, whereas high nuclear levels of microcephalin and an
absence of cytoplasmic microcephalin was associated with better
survival and lower tumour grade. A previous publication showed
that MCPH1 mutations caused the localisation of microcephalin to
change from nuclear to cytoplasmic, providing a plausible
explanation for our latter observations (Wu et al, 2009).
Interestingly, mutations of BRCA1 in EOC have been shown to
be responsible for a shift from nuclear to cytoplasmic localisation,
inhibiting nuclear DNA repair and transcription function
(Rodriguez et al, 2004). Similar effects may be seen with
microcephalin mutation. Unfortunately, we were unable to
consistently confirm a centrosomal localisation for microcephalin
in our cultures using the reagents available to us (Supplementary
Table 1), but we note that our conclusions are not incompatible
with the biological functions of microcephalin at this organelle
described by previous investigators (i.e., Tibelius et al, 2009).
In future studies it will be interesting to investigate associations
between microcephalin and ASPM levels and chemoresistance to
paclitaxel/carboplatin. Carboplatin reacts with DNA inhibiting
DNA replication and causing DNA breaks, whereas paclitaxel is a
mitosis-specific drug, binding specifically to microtubules and
inhibiting mitosis. Both of these modes of action could potentially
be impacted by changes in the functional activity of microcephalin
or ASPM. In conclusion, we have shown that ASPM and
microcephalin have variable expression levels in primary cultures
of malignant cells derived from ovarian tumour ascites and that
there are distinctive localisation patterns for both proteins. Our
data indicate that ASPM and microcephalin may be considered as
potential prognostic markers in ovarian cancer and further large-
scale studies are warranted.
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